Partner / Advisor

Pat has over 30 years of experience building, growing and turning around businesses and commercial enterprises around the world, most recently as CEO, President, and Board Member of Luminex Corporation (NASDAQ: LMNX).

During his ten year tenure, the company grew revenues at double-digit compounded rates and sales increased more than eight fold. During this period, gross margins improved by 3,000 basis points and the company transitioned from a loss position in 2004 to sector-leading levels of profitability.

Pat has an MBA from the Kellogg School of Management of Northwestern University. His undergraduate studies were at Princeton University and Spring Hill College.

Board Member Roles:

Pat serves as Chairman of Discovery Life Sciences, the world leader serving researchers in biospecimens and scientific services; as Chairman of Agendia, NV, a leader in clinical application of genomic science in breast cancer; and as independent director of Pattern Bioscience, an innovative clinical diagnostics company using technology to fight antibiotic resistance; and as a Director of MaxCyte (NASDAQ: MXCT), a world leader in cell and gene therapy enabling technologies.

Pat previously served as Director and Chairman of Oxford Immunotec (NASDAQ:OXFD) from 2016 through the company’s acquisition by Perkin Elmer (NYSE: PKI) in 2021. He also served as a Director of Personalis (NASDAQ: PSNL) from 2015 through 2021, including the company’s IPO in 2019